Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 999-1011

  Cherian, Christina ^a,b   Kugel Desmoulin, Sita ^a   Wang, Lei ^d   Polin, Lisa ^a,b   White, Kathryn ^a   Kushner, Juiwanna ^a   Stout, Mark ^c   Hou, Zhanjun ^a,b   Gangjee, Aleem ^d   Matherly, Larry H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

Antifolate; Folate; Mesothelioma; Pemetrexed; Proton coupled folate transporter

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTON COUPLED FOLATE TRANSPORTER; PYRROLO[2,3 D]PYRIMIDINE THIENOYL ANTIFOLATE DERIVATIVE; UNCLASSIFIED DRUG; FOLIC ACID ANTAGONIST; POLYGLUTAMIC ACID; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; MESOTHELIOMA; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; FEMALE; FOLIC ACID ANTAGONISTS; HELA CELLS; HUMANS; MESOTHELIOMA; MICE; MICE, SCID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; PROTON-COUPLED FOLATE TRANSPORTER; PYRIMIDINES; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84878840411     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2094-0     Document Type: Article

References (40)

1. Beardsley GP, Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333 (Pubitemid 19027608)
2. Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417 (Pubitemid 46332443)
3. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R (1997) Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15:207-218 (Pubitemid 27453875)
4. Cugell DW, Kamp DW (2004) Asbestos and the pleura: a review. Chest 125:1103-1117 (Pubitemid 38367306)
5. Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, Gangjee A (2008) Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem 51:5052-5063
6. Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, Gangjee A (2009) Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 52:2940-2951
7. Fabre G, Fabre I, Matherly LH, Cano JP, Goldman ID (1984) Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem 259:5066-5072 (Pubitemid 14140609)
8. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136-147 (Pubitemid 351972085)
9. Garland LL (2011) Chemotherapy for malignant pleural mesothelioma. Curr Treat Options Oncol 12:181-188
10. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65:11721-11728 (Pubitemid 41821733)
11. Goldman ID, Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28:77-102 (Pubitemid 15015465)
12. Hazarika M, White RM, Johnson JR, Pazdur R (2004) FDA drug approval summaries: pemetrexed (Alimta). Oncologist 9:482-488 (Pubitemid 39332311)
13. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177-182 (Pubitemid 27064702)
14. Henderson GB, Zevely EM (1983) Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochem Int 6:507-515 (Pubitemid 13107303)
15. Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, Wloszczynski PA, Moin K, Matherly LH (2011) Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 287:4982-4995
16. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR (2006) Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13:255-263 (Pubitemid 44600936)
17. Kugel Desmoulin S, Hou Z, Gangjee A, Matherly LH (2012) The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 13:1355-1373
18. Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH (2011) Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 80:1096-1107
19. Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH (2012) Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol 82:591-600
20. Kugel Desmoulin S, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A, Matherly LH (2010) Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d] pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 78:577-587
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
22. Matherly LH, Hou Z, Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111-128 (Pubitemid 46452186)
23. Nutt JE, Razak AR, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J (2010) The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 102:553-560
24. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ (1995) Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59:835-844
25. Polin LCT, Roberts BJ, Lawson AJ, Leopold WR III, White K, Kusner J, Paluch J, Hazeldine S, Moore R, Rake J, Horwitz JP (2011) Transplantable syngeneic tumors: solid tumors of mice. Tumor models in cancer research. Humana Press, Inc., Totowa, NJ, pp 43-78
26. Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH (1997) Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15:99-108 (Pubitemid 27248249)
27. Polin L, White K, Kushner J, Paluch J, Simpson C, Pugh S, Edelstein MK, Hazeldine S, Fontana J, LoRusso P, Horwitz JP, Corbett TH (2002) Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20:13-22 (Pubitemid 34251647)
28. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928 (Pubitemid 44792250)
29. Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669-C1678 (Pubitemid 350085626)
30. Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, Gillies RJ (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57:309-312 (Pubitemid 29056209)
31. van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61:3675-3681 (Pubitemid 32694979)
32. Varela-Moreiras G, Selhub J (1992) Long-term folate deficiency alters folate content and distribution differentially in rat tissues. J Nutr 122:986-991
33. Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, Gangjee A (2012) Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem 55:1758-1770
34. Wang L, Cherian C, Kugel Desmoulin S, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 53:1306-1318
35. Wang L, Kugel Desmoulin S, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A (2011) Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. J Med Chem 54:7150-7164
36. Wike-Hooley JL, Haveman J, Reinhold HS (1984) The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343-366 (Pubitemid 15166545)
37. Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727 (Pubitemid 38180440)
38. Zhao R, Goldman ID (2007) The molecular identity and characterization of a proton-coupled folate transporter - PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129-139 (Pubitemid 46452187)
39. Zhao R, Matherly LH, Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4
40. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854-862